Acumen Q2 net loss $10.2M; cash $209.9M; Phase 1 topline H1 2023; director resigns

Acumen Pharmaceuticals, Inc.

2022-Q2 EPS reported -$0.48

Cash, cash equivalents and marketable securities $209.9M as of June 30, 2022; expected runway through 2025.
Net loss $10.2M for Q2 2022 vs $61.4M in Q2 2021 (2021 incl $57.9M non-cash liability charge).
R&D expenses $7.3M (up from $2.3M) due to ongoing Phase 1 INTERCEPT-AD trial.
Phase 1 INTERCEPT-AD topline results expected H1 2023; 15 active sites recruiting.
Dr. Jeffrey Sevigny resigned from Board effective Aug 12, 2022 due to employment requirements, not disagreement.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey Sevigny

Director

ABOS · Acumen Pharmaceuticals, Inc.

Effective: 2022-08-12
Filed: August 15, 2022, 7:59 PM ET

On August 12, 2022, Dr. Jeffrey Sevigny notified the Board of Directors of his resignation from the Board of Directors, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey Sevigny resigned as Director at Acumen Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 12, 2022, Dr. Jeffrey Sevigny notified the Board of Directors of his resignation from the Board of Directors, effective immediately.

View on SEC.gov

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-221242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.